The prevalence of cases of Gastroparesis in the USA is 268 to 339 cases per 100,000 population in the USA was more than twice as common in females than in male individuals, highest in patients aged 58 to 64 years, and lowest in patients aged 18 to 27 years. The prevalence of diabetic gastroparesis ranges between 101 to 105 cases, per 100,000 persons, whereas the prevalence of diabetic gastroparesis among patients with type 1 and type 2 diabetes was 10.4 and 91.0.
Read more:- Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Comprehensive insight on patient segmentation based on age, sex, by etiology (T1DM, T2DM, Postsurgical, Drug-induced, Idiopathic, and Other types; Scleroderma, Lupus, Hypothyroidism, Parkinson disease, Cerebral palsy, Multiple sclerosis) and others undefined, severity (Mild, Moderate, and severe), Settings; Refractory cases, Signs & Symptoms, Clinical Manifestations, and has been provided into the epidemiology section of the Gastroparesis and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are few drug candidates/biologicals are in different Phase (Phase I, II & III) stages of development. Key companies are Theravance Biopharma, PTC Therapeutics, CinDome Pharma, Inc., Vanda Pharmaceuticals, GlaxoSmithKline, Bird Rock Bio, Inc., Evoke Pharma, Neurogastrx, Inc., Ironwood Pharmaceuticals, Inc., Takeda, Millennium Phar-maceuticals, Inc., Forest Laboratories, Motus Therapeutics, Inc., and few others. Gastroparesis (GP) has long been in dire need of novel therapies, given the aggressive nature and poor prognosis in the refractory setting. One of the major limitations to drug development is that clinical trials tend to enroll a large number of Gastroparesis severity.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
GM2 Gangliosidosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Lyme Disease – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Subarachnoid hemorrhage (SAH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
ANCA-Associated Vasculitis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Factor VII Deficiency – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English